Expanded Access WR 279396 Topical Cream Treatment for Uncomplicated Cutaneous Leishmaniasis (WR279396RX)
This is an expanded access treatment protocol designed to provide a topical cream treatment option to military health care beneficiaries with parasitologically confirmed uncomplicated Cutaneous Leishmaniasis.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||WR 279,396 (Paromomycin + Gentamicin Topical Cream) Treatment Program for Individuals With Uncomplicated Cutaneous Leishmaniasis|
Drug: WR 279,396
When a military health care beneficiary presents at a Department of Defense Military Treatment Facility with a skin lesion clinically and epidemiologically consistent with suspicious Cutaneous Leishmaniasis, routine diagnostic parasitology testing will be performed as standard of care, and if there is a positive diagnosis, the patient will be offered the option to participate in this treatment program and after providing written informed consent/assent., if eligible to participate, the patient will receive treatment with WR 279,396.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01641796
|Contact: Naomi Aronson, MDfirstname.lastname@example.org|
|Contact: Timothy Whitman, DOemail@example.com|
|United States, Maryland|
|Military Treatment Facilities|
|Multiple, Maryland, United States|
|Contact: Naomi Aronson, MD firstname.lastname@example.org|
|Principal Investigator: Naomi Aronson, MD|
|Principal Investigator:||Naomi Aronson, MD||Uniformed Services University of the Health Sciences|